Amaravati / Bengaluru, 26 May 2026 — Remidio Innovative Solutions has won First Place under the Point of Care Devices category at the Andhra Pradesh MedTech Innovation Challenge, announced at the programme’s grand finale today during the AI-Driven Health Systems: Strategic Stakeholder Engagement Workshop and MedTech Innovation Challenge Grand Finale, held at the Ratan Tata Innovation Hub (RTIH), Mangalagiri, in the Amaravati capital region.
The recognition follows the deployment of Remidio’s InstaEyeClinic Kit at Government Medical College and Hospital (GMCH), Guntur, where AI-enabled portable eye screening was run inside a government hospital by paramedical staff, with no ophthalmologist on site.
What was deployed
The InstaEyeClinic Kit combines three handheld devices, a fundus camera, a portable slit lamp and an autorefractometer, with Remidio’s offline MediosHI AI in a single battery-operated carrycase. It screens for conditions like diabetic retinopathy, glaucoma, age-related macular degeneration, cataract and refractive error, in under ten minutes per patient, with AI results delivered on-device and without an internet connection.
Pilot outcomes at GMCH Guntur
Over seven active screening weeks (9 February to 30 March 2026), the pilot completed 339 retinal examinations, 213 anterior-segment exams and 489 refraction tests, operated entirely by GMCH paramedical staff. The AI flagged 22 diabetic retinopathy, 10 macular degeneration and 6 glaucoma cases, generating 38 referrals into the hospital’s ophthalmology OPD. The macular degeneration cases were the first ever screened for at the facility.
Workshop presentation
At the workshop, Dr. Anand Sivaraman, Director and CEO of Remidio, presented “Oculomics for the Next Billion: How an AI-enabled Retinal Camera can Revolutionise Health Intelligence,” on using the retina as a non-invasive window for earlier detection and population-scale health intelligence.
About the challenge
The MedTech Innovation Challenge is an Andhra Pradesh government initiative run through the Ratan Tata Innovation Hub. Eighteen startups ran live pilots in government hospitals across four categories, collectively serving close to 15,000 patients over the programme window under clinical supervision. Winners were selected by the Committee for Applied Technologies in Health (CATH) on the strength of real-world clinical outcomes, with total cash incentives of Rs 40 lakh across the winning startups.
“AI is enabling low-cost, high-quality diagnostic services, reducing the burden of non-communicable diseases, and helping families avoid heavy medical expenses. It can serve as an important tool in improving people’s quality of life, as the government proactively adopts emerging technologies across all sectors with a futuristic vision. The dreams of ‘Viksit Bharat’ and ‘Viksit Andhra Pradesh’ could be achieved faster only when people remain healthy.”
— Health Minister Shri Satya Kumar Yadav
“This recognition belongs to the GMCH Guntur team, and to the Andhra Pradesh government for testing technology where it counts, inside a public hospital with real patients. It also reflects the visionary leadership of Chief Minister Shri Chandrababu Naidu and Health Minister Shri Satya Kumar Yadav, whose commitment to technology led governance is positioning Andhra Pradesh as a pioneer in AI driven healthcare. Five conditions screened in under ten minutes, by paramedical staff, with no specialist on site and no electricity, no internet connection, is exactly the access gap we set out to close. 10% was detected with retinal conditions, and 40% with refractive disorders that routine screening would have missed.
The next step is oculomics, reading systemic risk from the same retinal scan, and we are grateful to be trusted with that work at scale.”
— Dr. Anand Sivaraman, Director and CEO, Remidio Innovative Solutions
About the device
InstaEyeClinic Kit
Early Detection Of At-Risk Patients And Monitoring By Bringing Eye Testing Closer To The Patient.
World’s First Comprehensive Eye Screening Kit
- Anterior segment imaging for screening conditions like cataracts, eye infections, and more.
- Posterior segment imaging for conditions like glaucoma,
diabetic retinopathy, and AMD. - Uncorrected refractive error measurement.
- An Eye Clinic In A Backpack
- Compact, portable, light weight, easy to use by anyone, with minimal training.
- Our edge AI-enabled devices lets you screen for all common eye conditions offering a comprehensive evaluation of the eye in under 10 mins.
- Remotely review patient data stored securely & privately on the cloud.
Seamless Telemedicine Experience An Eye Clinic
Remotely review patient data stored securely & privately on the cloud. Integrated analytics platform for unique insights.
Regulatory Approvals
CDSCO Approved
Videos:
https://www.youtube.com/watch?v=t4DiRaq071c&t=4s
https://www.youtube.com/watch?v=SeGh5Ok75s4
https://www.youtube.com/watch?v=kNafFtpnU-Q
About Remidio –
Today, the human eye is unlocking early insights into systemic health, and Remidio is at the forefront of this transformation. Remidio is a pioneer in AI-driven eye care, leading the shift from care of the eye to healthcare through the eye. As the first company to receive CDSCO approval in India for our adaptive ophthalmic AI, in addition to CE marking in Europe under Class II EU-MDR, we are redefining how diseases like diabetic retinopathy, glaucoma, and AMD are detected early, in close to patient contexts, while remaining confident of extending this to systemic disease detection such as CVD, CKD and liver diseases, in the future.
With CE-marked, FDA 510(k)-registered devices, our solutions have screened 16 million+ patients across 55 countries, integrating teleophthalmology and AI for fast, accurate diagnoses. Our innovative retinal imaging solutions ensure precision and efficiency in clinical workflows. Our journey began humbly – thanks to the chance meeting of our founder, with a mission driven ophthalmologist, who brought into focus the need for decentralizing eye testing with simple to use and affordable devices. That conversation, 15 years back, sparked a vision to make high-quality preventive care accessible to all. Guided by innovation, empathy, and a commitment to global impact, our journey is just beginning!
